Neuroscientific Biopharmaceuticals Ltd has released a press release.
NSB 1HY22 Key Activity Highlights
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- Successful completion of key studies in lead up to Phase I
- Positive off-target safety assessment of EmtinB
- Positive results in biomarker characterisation of Emtins
- Completion of Safety Pharmacology Studies
- NSB Receives R&D Advance & Overseas Finding
Later from Neuroscientific Biopharmaceuticals
- New data demonstrates EmtinB activity in autoimmune diseases
- Positive safety result supports advance to clinical trials
- HREC Submission for early-phase Clinical Trial
- Ethics Approval Granted for Early-Phase Clinical Trial
- Positive results in MS animal study
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals